4. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, et al. (2009) Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 48: 239–247. 5. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158. 6. Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, et al. (2010) Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. Aids 25: 325–333. 7. Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, et al. (2009) Low- frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 52: 569–573. 8. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, et al. (2010) Prevalence and clinical significance of HIV drug resistance mutations by ultra- deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 5: e10952. 9. Toni TA, Asahchop EL, Moisi D, Ntemgwa M, Oliveira M, et al. (2009) Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 53: 1670–1672. 10. Balduin M, Oette M, Daumer MP, Hoffmann D, Pfister HJ, et al. (2009) Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure. J Clin Virol 45: 34–38. 11. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, et al. (2008) Transmission of HIV-1 minority-resistant variants and response to first- line antiretroviral therapy. Aids 22: 1417–1423. 12. Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, et al. (2010) Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol 50: 156–161. 13. Jakobsen MR, Tolstrup M, Sogaard OS, Jorgensen LB, Gorry PR, et al. (2010) Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 50: 566–573. 14. Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, et al. (2009) Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation 454 in Heavily Pre-Treated HIV+ Subjects nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 52: 309–315. 15. Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, et al. (2009) Low- abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE 4: e6079. 16. D’Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, et al. (2010) Tenofovir (TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV Type 1 Subpopulations During Failure with Persistent Viremia as Detected by Ultradeep Pyrosequencing. AIDS Res Hum Retroviruses 27: 201–209. 17. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437: 376–380. 18. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, et al. (2005) HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 192: 456–465. 19. Van Laethem K, Geretti A, Camacho R, Vandamme AM. Algorithm for the use of genotypic HIV-1 resistance data. Rega v8.0.2 Leuven, 16 June 2009. 20. Shikuma CM, Yang Y, Glesby MJ, Meyer WA, 3rd, Tashima KT, et al. (2007) Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 44: 540–550. 21. Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, et al. (2008) Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother 52: 3237–3243. 22. Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, et al. (2006) Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 11: 421–429. 23. Yates PJ, Hazen R, St Clair M, Boone L, Tisdale M, et al. (2006) In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. Antimicrob Agents Chemother 50: 1092–1095. 24. de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, et al. (2008) Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 24: 379–388. 25. Shao W, Boltz VF, Kearney M, Maldarelli F, Mellors JM, et al. (2009) Characterization of HIV-1 sequence artifacts introduced by bulk PCR and detected by 454 sequencing. XVIII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications. Fort Myers, FL, USA 9- 13 June 2009 (Abstract 104). Antiviral Therapy 14(Suppl 1): A123. PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19461